CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...